Trevi Therapeutics (TRVI) Stock Analysis & Winston Score

Trevi Therapeutics is a small biotech company focused on developing drugs to treat serious medical conditions that don't have many good treatment options. Its lead drug candidate is nalbuphine ER, which targets chronic prurigo nodularis (a severe skin itching disorder) and potentially other conditions involving the nervous system. The company's main customers would be patients and healthcare providers, and it operates in the specialty pharmaceutical space. Trevi makes no product revenue yet because its drugs are still in clinical development and have not received regulatory approval. The company is based in New Haven, Connecticut, and funds its operations through equity raises and partnerships rather than product sales — which explains its negative returns and zero margins. The key growth driver is winning FDA approval for nalbuphine ER, but the main risk is that clinical trials could fail or approval could be delayed, which would put significant pressure on the company's cash runway and ability to continue operating.